ProPhase Labs, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price
ProPhase Labs, Inc. (PRPH) had Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price of $6.01 per share as of 2024-12-31, per its 10-K filed 2025-04-01.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice · last filed 2025-04-01
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $6.01.
- 2024-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $6.01.
- 2024-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $6.01.
- 2024-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $6.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price |
|---|---|
| 2024-12-31 | $6.01 10-K · filed 2025-04-01 |
| 2024-09-30 | $6.01 10-Q · filed 2024-11-13 |
| 2024-06-30 | $6.01 10-Q · filed 2024-08-14 |
| 2024-03-31 | $6.00 10-Q · filed 2024-05-10 |
| 2023-12-31 | $8.65 10-K · filed 2025-04-01 |
| 2023-09-30 | $8.65 10-Q · filed 2024-11-13 |
| 2023-06-30 | $8.65 10-Q · filed 2024-08-14 |
| 2023-03-31 | $6.84 10-Q · filed 2024-05-10 |
| 2022-12-31 | $10.03 10-K · filed 2024-03-29 |
| 2019-12-31 | $2.01 10-K · filed 2020-03-26 |
| 2018-12-31 | $2.52 10-K · filed 2020-03-26 |
| 2017-12-31 | $2.01 10-K · filed 2019-03-26 |
| 2014-12-31 | $1.54 10-K · filed 2015-03-27 |
| 2013-12-31 | $1.31 10-K · filed 2014-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |